Tandem Mobi: Tubed and Tubeless Automated Insulin Delivery

Tandem MobiTandem Mobi tubeless is a new way to wear the Tandem Mobi insulin pump directly on your body, with no tubing in between. The FDA cleared the tubeless cartridge and infusion set in November 2026, and Tandem plans to launch them in the U.S. in the first half of 2027.

This article explains what the FDA cleared, what “up to 7 days of wear” really means, how Control-IQ+ automated insulin delivery works on the Mobi, which CGMs are compatible, and how the tubeless Mobi compares with Omnipod 5.

Jump to Frequently Asked Questions ↓

Key Points

  • Tubeless option cleared: In November 2026, the FDA cleared a new tubeless cartridge and infusion set that lets the existing Tandem Mobi pump be worn directly on the skin, without tubing.
  • Same pump, two ways to wear it: Users can switch between tubed and tubeless wear by changing supplies. Current in-warranty Mobi users do not need a new pump.
  • About the “7 days”: The tubeless infusion set is cleared for up to 7 days of wear, but the insulin cartridge is cleared for 3 days of use.
  • Not available yet: U.S. launch is planned for the first half of 2027, through pharmacy benefits only.
  • Who it’s for: Control-IQ+ is cleared for type 1 diabetes (age 2 and older) and type 2 diabetes (age 18 and older), and for pregnancy with type 1 diabetes when used with a CGM suitable for pregnancy.

What Is the Tandem Mobi?

The Tandem Mobi is a small, durable (reusable) insulin pump from Tandem Diabetes Care of San Diego. Paired with a compatible continuous glucose monitor (CGM) and Tandem’s Control-IQ+ algorithm, it forms an automated insulin delivery (AID) system, also known as a hybrid closed-loop system. Tandem describes it as the world’s smallest durable AID system; it is roughly half the size of the company’s t:slim X2 pump.

The Mobi has no screen. It is controlled via the Tandem Mobi smartphone app, with a single button on the pump to deliver a preset bolus when the phone isn’t handy. Its standard cartridge holds up to 200 units of rapid-acting U-100 insulin. The pump has a rechargeable battery with wireless charging and can be clipped to clothing, carried in a pocket, or worn on the body with an adhesive sleeve and short tubing.

Until now, every Mobi has used a conventional tubed infusion set. The November 2026 clearance adds a second option: a tubeless configuration that attaches the pump directly to the body.

What Did the FDA Clear in November 2026?

On November 12, 2026, the FDA cleared Tandem Mobi for tubeless insulin delivery with a new cartridge and infusion set. Tandem announced the clearance the following day. The clearance covers two new disposable components, a Tandem Mobi tubeless cartridge and a tubeless infusion set, which convert the current Mobi pump into an on-body device. Tandem calls it the first and only tubeless AID system with up to 7 days of wear.

The pump itself has not changed. Tandem says the Mobi was designed from the start to support different wear options, and the pump is now cleared for both tubed and tubeless insulin delivery. Users select the configuration by choosing their supplies.

Tandem Mobi Timeline

Date Milestone
July 2023 FDA clears Tandem Mobi for people with diabetes age 6 and older
Early 2024 U.S. commercial launch; indication later expanded to age 2 and older
May 2024 Dexcom G7 integration launches
2025 Control-IQ+ replaces Control-IQ; type 2 diabetes indication (adults 18+) cleared
Nov 2025 / Mar 2026 Android app cleared by FDA; launched in the U.S. in March 2026
2026 Dexcom G7 15 Day integration; Mobi available in 12 international markets (Sept)
Nov 2026 FDA clears tubeless cartridge and infusion set
1H 2027 (planned) Full U.S. launch of tubeless supplies through pharmacy

How Does Tubeless Wear Work, and What Does “7 Days” Mean?

In the tubeless configuration, the Mobi pump connects to a tubeless cartridge and an infusion set that adheres to the skin, so insulin travels directly from the pump into the body without any tubing. Because the pump is durable and rechargeable, it is reused; only the cartridge and infusion set are disposable.

The headline “up to 7 days of wear” requires one important clarification:

  • The infusion set (the part inserted under the skin) is cleared for up to 7 days of wear.
  • The cartridge (which holds the insulin) is cleared for 3 days of use.

In practice, this means users can expect to change the insulin cartridge about every 3 days but may be able to keep the same infusion site in place for up to a week. Fewer site changes can mean fewer insertions and less skin irritation for some people, but it does not mean a once-a-week routine.

The seven-day duration is the maximum cleared wear time, not a requirement to leave the infusion set in place for seven days. A set should be replaced sooner if insulin delivery is disrupted, the site becomes irritated, or another problem develops.

Tandem has not yet published full details of the tubeless hardware, including the cannula design, adhesive, insulin capacity of the tubeless cartridge, and water-exposure instructions for the tubeless configuration. We will update this article when the instructions for use and product specifications are available.

When Will Tandem Mobi Tubeless Be Available?

The FDA cleared Tandem Mobi for tubeless insulin delivery on November 12, 2026, and Tandem announced the clearance the next day.

Full commercial availability in the United States is planned for the first half of 2027. The new tubeless cartridge and infusion set will be distributed through pharmacies to eligible customers with pharmacy benefits. Tandem estimates that pharmacy coverage for Mobi currently reaches about half of insured people in the U.S. and expects that share to increase.

Existing in-warranty Mobi users will not need to replace their pumps. Tandem plans to contact eligible customers once the new supplies become available.

The launch date remains a company projection and may change. Pricing and individual insurance coverage have not yet been announced.

How Does Control-IQ+ Work with the Tandem Mobi?

Chart of how Control-IQ+ adjusts insulin at different predicted blood sugar levels.Control-IQ+ uses continuous glucose monitor (CGM) readings to predict glucose levels 30 minutes in advance and automatically adjusts insulin delivery every five minutes. The algorithm is the same whether the Mobi is worn with or without tubing.

Under normal operation, Control-IQ+ responds to predicted glucose levels as follows:

Predicted glucose What Control-IQ+ does
Below 70 mg/dL (3.9 mmol/L) Stops basal insulin delivery
Below 112.5 mg/dL (6.2 mmol/L) Reduces basal insulin delivery
112.5–160 mg/dL (6.2–8.9 mmol/L) Generally maintains the programmed basal rate
Above 160 mg/dL (8.9 mmol/L) Increases basal insulin delivery
Above 180 mg/dL (10.0 mmol/L) May deliver an automatic correction bolus (AutoBolus), up to once per hour

Automatic correction boluses deliver 60% of the calculated correction toward a glucose level of 110 mg/dL (6.1 mmol/L), taking into account insulin already active in the body.

Sleep and Exercise Activity

Control-IQ+ also offers two optional activity settings. Sleep activity uses a narrower treatment range of 112.5–120 mg/dL (6.2–6.7 mmol/L) and does not deliver automatic correction boluses. Exercise activity uses a higher treatment range of 140–160 mg/dL (7.8–8.9 mmol/L) to reduce the risk of hypoglycemia (low blood sugar). Automatic correction boluses may still occur during Exercise activity.

These treatment ranges differ from the standard time-in-range goal of 70–180 mg/dL (3.9–10.0 mmol/L) used in CGM reports.

What’s New in Control-IQ+

Unlike the original Control-IQ, Control-IQ+ supports temporary basal rates while automation remains active. During a temp rate, Control-IQ+ continues to adjust basal insulin and can still deliver automatic correction boluses, even when the temp rate is set to 0%. Control-IQ+ also permits extended boluses of up to eight hours, and its insulin action duration is fixed at five hours. It supports a wider range of body weights and total daily insulin doses than Control-IQ, helping support its expansion to adults with type 2 diabetes.

Control-IQ+ remains a hybrid closed-loop system. Users still need to deliver meal boluses and actively manage their diabetes.

Who Can Use the Tandem Mobi?

The Tandem Mobi pump requires a prescription and is indicated for people ages 2 and older who require insulin. Control-IQ+ is cleared for:

  • People with type 1 diabetes age 2 and older
  • Adults with type 2 diabetes age 18 and older
  • Pregnancy complicated by type 1 diabetes, when used with a CGM suitable for use during pregnancy

Control-IQ+ should not be used by anyone under age 2, by people using less than 5 units of insulin per day, or by people weighing less than 20 pounds (9 kg). Like any AID system, it does not replace active diabetes management, and a healthcare provider should help determine whether it is a good fit.

Which CGMs Are Compatible With the Tandem Mobi?

CGM Works with Mobi? Notes
Dexcom G7 (10-day) Yes Integrated since May 2024; indicated for ages 2+
Dexcom G7 15 Day Yes Requires updated pump and app software; indicated for adults 18+
Dexcom G6 Compatible; manufacturing discontinued Dexcom ended G6 manufacturing on July 1, 2026. Supplies may remain available while inventory lasts; users are being moved to G7
FreeStyle Libre 3 Plus Not yet (planned) Works with the t:slim X2. Tandem has confirmed plans to add it to Mobi but has not announced a release date
FreeStyle Libre 2 Plus No Works with the t:slim X2 only

As of November 2026, the Tandem Mobi is not compatible with the FreeStyle Libre 3 Plus CGM. Although Tandem’s t:slim X2 pump supports the sensor and Tandem has confirmed plans to add support for the sensor to the Mobi system, the company has not announced a release date.

The Mobi communicates directly with the Dexcom G7 sensor. CGMs are prescribed and sold separately from the pump.

Standard Tandem Mobi Pump Specifications

The specifications below apply to the Tandem Mobi pump with its standard cartridge. Tandem has not yet published complete specifications for the new tubeless cartridge. The standard Mobi pump holds 200 units of insulin.

Feature Tandem Mobi
Dimensions 2.02 x 1.47 x 0.56 inches (5.13 x 3.73 x 1.42 cm), roughly half the size of t:slim X2
Weight 1.06 oz (30 g) with a full cartridge
Insulin capacity Up to 200 units (2.0 mL) of U-100 insulin (Humalog or NovoLog)
Basal rate 0 or 0.1–15 U/hr
Basal increments 0.001 U/hr at programmed rates of at least 0.1 U/hr
Basal rate limit 0.2–15 U/hr; default 3 U/hr
Basal profiles Up to 6 personal profiles, with up to 16 basal segments each
Temporary basal 15 minutes to 72 hours; available with Control-IQ+ active
Extended bolus Up to 8 hours with Control-IQ+
Insulin action duration Fixed at 5 hours with Control-IQ+
Bolus range 0.05 to 25 units, in 0.01-unit increments
Screen None; full control through the smartphone app
On-pump button Delivers a preset bolus without the phone
Phone compatibility Selected iPhone and Android models (see Tandem’s compatibility list)
Battery Rechargeable, with wireless charging
Water resistance IP28: tested to 8 feet (2.4 m) for 2 hours (pump and standard cartridge, as manufactured)
Wear options Clip, pocket, on-body with adhesive sleeve and 5-inch tubing, or tubeless (from 1H 2027)
Tubed infusion sets All Tandem-branded sets, including AutoSoft 90, AutoSoft 30, AutoSoft XC, VariSoft, and TruSteel

Water resistance can decline if the pump is damaged or worn, and Tandem advises against using it in hot tubs or saunas. Water-exposure instructions for the tubeless configuration have not yet been published.

Not all smartphones are compatible with the Tandem Mobi app. Check your model on Tandem’s device compatibility page before starting.

How Does the Tubeless Mobi Compare to Omnipod 5?

Until now, Insulet’s Omnipod 5 has been the primary tubeless AID option in the U.S. The two systems take different approaches:

  Tandem Mobi (tubeless) Omnipod 5
Design Durable, rechargeable pump plus disposable cartridge and infusion set Fully disposable pod
Change schedule Cartridge every 3 days; infusion set up to 7 days Pod every 3 days (72 hours)
Can switch to tubing? Yes, same pump No
Algorithm Control-IQ+ (112.5–160 mg/dL [6.2–8.9 mmol/L]; automatic correction boluses) SmartAdjust: selectable glucose targets of 100–150 mg/dL (5.6–8.3 mmol/L) in 10 mg/dL increments (updated algorithm)
Control Smartphone app plus on-pump bolus button Omnipod 5 app or Insulet controller
CGMs Dexcom G7 and G7 15 Day (G6 discontinued); Libre 3 Plus planned Dexcom G6 and G7; FreeStyle Libre 2 Plus and Libre 3 Plus
Ages Type 1: 2+; type 2: 18+ Type 1: 2+; type 2: 18+
Availability Planned for 1H 2027 (pharmacy) Available now (pharmacy)

For a broader look at every current pump, see our Best Insulin Pumps of 2026: A Complete Comparison Guide.

Tubed or Tubeless: Which Wear Option Is Right for You?

Tubeless wear may be suitable for people who:

  • Want nothing to snag on doorknobs, seat belts, or sports equipment
  • Prefer fewer infusion site insertions (up to 7 days per site)
  • Like an all-on-body setup for sleep and daily activities

Tubed wear may suit people who:

  • Want to disconnect quickly for a shower or swim while leaving the site in place
  • Prefer to keep the pump off the body, clipped on or in a pocket
  • Already have a familiar infusion set and site routine that works well

Because both options use the same pump, Mobi users who are unsure can try one configuration and switch later, subject to their prescription and insurance coverage for supplies.

What Should Current Mobi Users Do?

  1. Keep your pump. If your Mobi is under warranty, you won’t need a new one due to tubeless wear.
  2. Check your insurance. Find out whether your plan covers Mobi supplies under the pharmacy benefit.
  3. Talk with your care team about whether tubeless wear is appropriate for your sites, skin, and routine.
  4. If you still use Dexcom G6, ask about upgrading to Dexcom G7 now that G6 is being discontinued.
  5. Watch for Tandem’s outreach in 2027, when tubeless supplies become available.

What Other Automated Insulin Delivery Systems Are Available?

If you are comparing options, see our overview of automated insulin delivery systems and our guides to individual systems:

For help choosing between tubed sets, see how to choose an infusion set.

Helpful Resources

Frequently Asked Questions

Is the tubeless Tandem Mobi available yet?

Not yet. The FDA cleared the tubeless cartridge and infusion set on November 12, 2026, and Tandem plans a full U.S. launch in the first half of 2027. The launch date is a company projection and may change.

Do I need a new pump to use the tubeless setup?

No. The tubeless cartridge and infusion set are compatible with the existing Tandem Mobi pump. Tandem says customers with an in-warranty Mobi will not need a new pump.

How long can I wear the Mobi tubeless?

The tubeless infusion set is cleared for up to 7 days of wear, but the insulin cartridge is cleared for 3 days of use, so cartridge changes will still occur about every 3 days.

Can I switch between wearing tubed and tubeless?

Yes. The Mobi pump is cleared for both tubed and tubeless delivery. You switch by changing the supplies you use.

Is the Tandem Mobi approved for treating type 2 diabetes?

Yes. Control-IQ+ technology is cleared for adults with type 2 diabetes aged 18 and older, as well as for people with type 1 diabetes aged 2 and older.

What is the minimum age for the Tandem Mobi?

The Mobi and Control-IQ+ can be used by people with type 1 diabetes as young as 2 years old. Control-IQ+ should not be used by people who weigh less than 20 pounds or use less than 5 units of insulin per day.

Which CGMs are compatible with the Tandem Mobi?

The Mobi works with the Dexcom G7 and Dexcom G7 15 Day. It also works with the Dexcom G6, which is being discontinued. The Mobi does not yet work with the FreeStyle Libre 3 Plus. Tandem has confirmed plans to add support for it but has not announced a release date.

Does the Tandem Mobi work with Android smartphones?

Yes. The Android version of the Tandem Mobi app was cleared by the FDA in November 2025 and launched in the U.S. in March 2026. The app also works with select iPhone models. Check Tandem’s device compatibility list to confirm your phone is supported.

Is the Mobi tubeless waterproof?

The Mobi pump, with its standard cartridge, is rated IP28 (tested to 8 feet for 2 hours) as manufactured, and Tandem advises against use in hot tubs and saunas. Tandem has not yet published water-exposure instructions for the tubeless configuration, so once it launches, check the instructions for use before swimming with it.

Will insurance cover the Mobi tubeless supplies?

The tubeless supplies will be sold only through the pharmacy to people with pharmacy benefits. Tandem estimates that current pharmacy coverage for Mobi is about half of insured people in the U.S. and expects it to expand.

Last Updated on November 19, 2026